Comparison of Household Transmission of Influenza Virus From Index Patients Treated With Baloxavir Marboxil or Neuraminidase Inhibitors: A Health Insurance Claims Database Study

扎那米韦 医学 奥司他韦 神经氨酸酶抑制剂 优势比 置信区间 神经氨酸酶 传输(电信) 入射(几何) 逻辑回归 内科学 病毒学 病毒 工程类 传染病(医学专业) 物理 疾病 光学 电气工程 2019年冠状病毒病(COVID-19)
作者
Takuji Komeda,Takahiro Takazono,Naoki Hosogaya,Eriko Ogura,Masakazu Fujiwara,Hideyuki Miyauchi,Yoshikazu Ajisawa,Shimpei Iwata,Hideaki Watanabe,Keiichi Honda,Yoshitake Kitanishi,Kanae Hara,Hiroshi Mukae
出处
期刊:Clinical Infectious Diseases [Oxford University Press]
卷期号:72 (11): e859-e867 被引量:14
标识
DOI:10.1093/cid/ciaa1622
摘要

Abstract Background Baloxavir marboxil (baloxavir) is expected to reduce influenza transmission by rapid reduction of viral load. The incidence of household transmission was compared between index patients (IPs) treated with baloxavir and those treated with neuraminidase inhibitors. Methods Using a Japanese claims database, the first family members with influenza diagnosis during the 2018–2019 influenza season were identified as IPs, and the diagnosis date was designated day 1. According to the anti-influenza drug dispensed to the IP, their families were classified into the oral baloxavir group and 3 controls: oral oseltamivir group (a primary control), inhaled zanamivir group, and inhaled laninamivir group. A household transmission was defined as influenza diagnosed for any non-IP family members during days 3−8. The incidence of household transmission was compared between groups using a logistic regression model adjusting backgrounds of IPs. Results The proportion of families with household transmission was 17.98% (15 226 of 84 672) in the baloxavir group and 24.16% (14 983 of 62 004) in the oseltamivir group. The covariate-adjusted odds ratio (oseltamivir/baloxavir) was 1.09 (95% confidence interval [95% CI], 1.05–1.12), which indicated significantly lower incidence in the baloxavir group. The adjusted odds ratios (controls/baloxavir) against zanamivir and laninamivir were 0.93 (95% CI, .89–.97) and 0.99 (95% CI, .96–1.02), respectively. Conclusions Baloxavir may contribute to reduction in household transmission compared with oseltamivir. In comparison between baloxavir and inhalants, a similar reduction was not shown and it might be due to unmeasured confounding by administration route differences.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
棱擎1号完成签到 ,获得积分10
刚刚
2秒前
tian发布了新的文献求助10
2秒前
panpanliumin完成签到,获得积分0
3秒前
普鲁卡因发布了新的文献求助10
5秒前
Keyuuu30完成签到,获得积分0
5秒前
5秒前
学者风范完成签到 ,获得积分10
7秒前
进退须臾完成签到,获得积分10
8秒前
图图发布了新的文献求助10
8秒前
liujinjin完成签到,获得积分10
9秒前
甜甜醉波完成签到,获得积分10
9秒前
小不完成签到 ,获得积分10
10秒前
小心薛了你完成签到,获得积分10
16秒前
与离完成签到 ,获得积分10
16秒前
感性的俊驰完成签到 ,获得积分10
20秒前
疯狂的凡梦完成签到 ,获得积分10
21秒前
桥豆麻袋完成签到,获得积分10
22秒前
量子星尘发布了新的文献求助10
23秒前
Hello应助幸福的杨小夕采纳,获得10
23秒前
Lighten完成签到 ,获得积分10
24秒前
lyj完成签到 ,获得积分10
25秒前
成就茗完成签到 ,获得积分10
27秒前
ZD完成签到 ,获得积分10
36秒前
38秒前
英姑应助普鲁卡因采纳,获得10
41秒前
冰糕发布了新的文献求助10
43秒前
BettyNie完成签到 ,获得积分10
45秒前
优雅的平安完成签到 ,获得积分10
45秒前
冰糕完成签到,获得积分10
50秒前
52秒前
852应助完犊子采纳,获得10
56秒前
ruochenzu发布了新的文献求助10
57秒前
不想洗碗完成签到 ,获得积分10
59秒前
const完成签到,获得积分10
1分钟前
hjx完成签到 ,获得积分10
1分钟前
稳重的尔安完成签到,获得积分10
1分钟前
量子星尘发布了新的文献求助10
1分钟前
缓慢的饼干完成签到 ,获得积分10
1分钟前
saturn完成签到 ,获得积分10
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038112
求助须知:如何正确求助?哪些是违规求助? 3575788
关于积分的说明 11373801
捐赠科研通 3305604
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022